TapewireFind a company

person · Reporting owner

Tessari Eben

Disclosed activity across 1 company

Tapewire entity
53251
SEC CIK
0001867899

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954CHIEF STRATEGY OFFICERApril 07, 2026April 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kiniksa Pharmaceuticals International, plc

Report date April 07, 2026 · Filed April 08, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Ordinary ShareSEC Table I · non-derivativeDirect23,130 Ending reported balance After 2026-04-07 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-04-07 · Exercise / conversion · Acquired 2,726 · Balance 23,976

F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

Row 2 · 2026-04-07 · Tax withholding · Disposed 846 · Balance 23,130

Restricted Share UnitSEC Table II · derivative / convertible securityDirect0 Reported balance After 2026-04-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-04-07 · Exercise / conversion · Disposed 2,726 · Balance 0

F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 08, 2024 Filed Apr 8, 2024 21:17 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionRestricted Share Unit · Derivative 2,726 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-010503 · form4-04082024_090409.xml · derivative · entry 6

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,573

Underlying: Class A Common Share · 2,726 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.

F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.

Read SEC document
April 08, 2024 Filed Apr 8, 2024 21:17 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Tax withholdingClass A Common Share 801 $17.90 $14,337.90
Disclosure

SEC source: 0001415889-24-010503 · form4-04082024_090409.xml · nonDerivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,024

Read SEC document
April 08, 2024 Filed Apr 8, 2024 21:17 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionClass A Common Share 2,726 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-010503 · form4-04082024_090409.xml · nonDerivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,825

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

Read SEC document
April 04, 2024 Filed Apr 8, 2024 21:17 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantRestricted Share Unit · Derivative 6,981 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-010503 · form4-04082024_090409.xml · derivative · entry 5

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,299

Underlying: Class A Common Share · 6,981 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F5 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter.

F5 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter.

Read SEC document
April 04, 2024 Filed Apr 8, 2024 21:17 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantPerformance Share Unit · Derivative 5,585 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-010503 · form4-04082024_090409.xml · derivative · entry 4

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,585

Underlying: Class A Common Share · 5,585 shares

Expires 2034-03-31

F3 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Common Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.

F4 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Common Share of the Issuer no later than January 30, 2027, unless such date falls on a non-business date, in which case the next business date shall apply.

Read SEC document
April 04, 2024 Filed Apr 8, 2024 21:17 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantShare Option · Derivative 36,300 $0.00 Strike: $18.06 $0.00
Disclosure

SEC source: 0001415889-24-010503 · form4-04082024_090409.xml · derivative · entry 3

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,300

Underlying: Class A Common Share · 36,300 shares

Expires 2034-03-31

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal month installments thereafter. The vesting commencement date is April 1, 2024.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 21:23 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionRestricted Share Unit · Derivative 1,773 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-010088 · form4-04032024_090445.xml · derivative · entry 3

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,318

Underlying: Class A Common Share · 1,773 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, April 1, 2023.

F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, April 1, 2023.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 21:23 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Tax withholdingClass A Common Share 521 $19.70 $10,263.70
Disclosure

SEC source: 0001415889-24-010088 · form4-04032024_090445.xml · nonDerivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,099

Read SEC document
April 01, 2024 Filed Apr 3, 2024 21:23 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionClass A Common Share 1,773 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-010088 · form4-04032024_090445.xml · nonDerivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,620

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

Read SEC document
March 01, 2024 Filed Mar 5, 2024 21:34 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionShare Option · Derivative 656 $0.00 Strike: $1.59 $0.00
Disclosure

SEC source: 0001415889-24-006702 · form4-03052024_090322.xml · derivative · entry 3

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,017

Underlying: Class A Common Share · 656 shares

Expires 2025-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on March 4, 2022.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
March 01, 2024 Filed Mar 5, 2024 21:34 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 SaleClass A Common Share 1,189 $22.03 $26,193.67
Disclosure

SEC source: 0001415889-24-006702 · form4-03052024_090322.xml · nonDerivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 122,847

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on March 4, 2022.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $22.03 and $22.055. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Read SEC document
March 01, 2024 Filed Mar 5, 2024 21:34 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionClass A Common Share 656 $1.59 $1,043.04
Disclosure

SEC source: 0001415889-24-006702 · form4-03052024_090322.xml · nonDerivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,036

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on March 4, 2022.

Read SEC document
September 02, 2023 Filed Sep 6, 2023 23:04 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionRestricted Share Unit · Derivative 1,964 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-013040 · form4-09062023_110948.xml · derivative · entry 8

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,928

Underlying: Class A Common Share · 1,964 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021.

F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021.

Read SEC document
September 02, 2023 Filed Sep 6, 2023 23:04 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Tax withholdingClass A Common Share 577 $17.76 $10,247.52
Disclosure

SEC source: 0001415889-23-013040 · form4-09062023_110948.xml · nonDerivative · entry 4

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,380

Read SEC document
September 02, 2023 Filed Sep 6, 2023 23:04 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionClass A Common Share 1,964 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-23-013040 · form4-09062023_110948.xml · nonDerivative · entry 3

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,957

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

Read SEC document
September 01, 2023 Filed Sep 6, 2023 23:04 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantShare Option · Derivative 42,544 $0.00 Strike: $17.76 $0.00
Disclosure

SEC source: 0001415889-23-013040 · form4-09062023_110948.xml · derivative · entry 7

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,544

Underlying: Class A Common Share · 42,544 shares

Expires 2033-08-31

F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.

Read SEC document
September 01, 2023 Filed Sep 6, 2023 23:04 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantRestricted Share Unit · Derivative 7,091 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-013040 · form4-09062023_110948.xml · derivative · entry 6

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,091

Underlying: Class A Common Share · 7,091 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023.

F3 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023.

Read SEC document
September 01, 2023 Filed Sep 6, 2023 23:04 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionRestricted Share Unit · Derivative 2,727 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-013040 · form4-09062023_110948.xml · derivative · entry 5

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,178

Underlying: Class A Common Share · 2,727 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022.

F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022.

Read SEC document
September 01, 2023 Filed Sep 6, 2023 23:04 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Tax withholdingClass A Common Share 801 $17.76 $14,225.76
Disclosure

SEC source: 0001415889-23-013040 · form4-09062023_110948.xml · nonDerivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,993

Read SEC document
September 01, 2023 Filed Sep 6, 2023 23:04 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionClass A Common Share 2,727 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-23-013040 · form4-09062023_110948.xml · nonDerivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,794

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

Read SEC document
April 10, 2023 Filed Apr 11, 2023 21:03 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionRestricted Share Unit · Derivative 2,727 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-006440 · form4-04112023_090449.xml · derivative · entry 3

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,178

Underlying: Class A Common Share · 2,727 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.

F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.

Read SEC document
April 10, 2023 Filed Apr 11, 2023 21:03 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Tax withholdingClass A Common Share 801 $10.71 $8,578.71
Disclosure

SEC source: 0001415889-23-006440 · form4-04112023_090449.xml · nonDerivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,067

Read SEC document
April 10, 2023 Filed Apr 11, 2023 21:03 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionClass A Common Share 2,727 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-23-006440 · form4-04112023_090449.xml · nonDerivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,868

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

Read SEC document
April 01, 2023 Filed Apr 3, 2023 20:30 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantRestricted Share Unit · Derivative 7,091 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-005788 · form4-04032023_040410.xml · derivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,091

Underlying: Class A Common Share · 7,091 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023.

F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023.

Read SEC document
April 01, 2023 Filed Apr 3, 2023 20:30 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantShare Option · Derivative 42,544 $0.00 Strike: $10.76 $0.00
Disclosure

SEC source: 0001415889-23-005788 · form4-04032023_040410.xml · derivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,544

Underlying: Class A Common Share · 42,544 shares

Expires 2033-03-31

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April1, 2023.

Read SEC document
March 20, 2023 Filed Mar 20, 2023 21:15 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionRestricted Share Unit · Derivative 2,982 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-005232 · form4-03202023_090331.xml · derivative · entry 6

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Share · 2,982 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F3 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs.

F3 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs.

Read SEC document
March 20, 2023 Filed Mar 20, 2023 21:15 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Tax withholdingClass A Common Share 876 $11.12 $9,741.12
Disclosure

SEC source: 0001415889-23-005232 · form4-03202023_090331.xml · nonDerivative · entry 4

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,141

Read SEC document
March 20, 2023 Filed Mar 20, 2023 21:15 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionClass A Common Share 2,982 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-23-005232 · form4-03202023_090331.xml · nonDerivative · entry 3

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,017

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

Read SEC document
March 16, 2023 Filed Mar 20, 2023 21:15 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionRestricted Share Unit · Derivative 1,964 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-005232 · form4-03202023_090331.xml · derivative · entry 5

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,928

Underlying: Class A Common Share · 1,964 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.

F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.

Read SEC document
March 16, 2023 Filed Mar 20, 2023 21:15 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Tax withholdingClass A Common Share 577 $11.46 $6,612.42
Disclosure

SEC source: 0001415889-23-005232 · form4-03202023_090331.xml · nonDerivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,035

Read SEC document
March 16, 2023 Filed Mar 20, 2023 21:15 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionClass A Common Share 1,964 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-23-005232 · form4-03202023_090331.xml · nonDerivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,612

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

Read SEC document
September 02, 2022 Filed Sep 6, 2022 20:09 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionRestricted Share Unit · Derivative 1,964 $0.00 $0.00
Disclosure

SEC source: 0001415889-22-009345 · form4-09062022_010905.xml · derivative · entry 6

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,892

Underlying: Class A Common Share · 1,964 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F5 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

F5 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

Read SEC document
September 02, 2022 Filed Sep 6, 2022 20:09 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Tax withholdingClass A Common Share 577 $11.44 $6,600.88
Disclosure

SEC source: 0001415889-22-009345 · form4-09062022_010905.xml · nonDerivative · entry 3

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,648

Read SEC document
September 02, 2022 Filed Sep 6, 2022 20:09 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionClass A Common Share 1,964 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-22-009345 · form4-09062022_010905.xml · nonDerivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,225

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

Read SEC document
September 01, 2022 Filed Sep 6, 2022 20:09 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantRestricted Share Unit · Derivative 10,905 $0.00 $0.00
Disclosure

SEC source: 0001415889-22-009345 · form4-09062022_010905.xml · derivative · entry 5

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,905

Underlying: Class A Common Share · 10,905 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F4 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.

F4 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.

Read SEC document
September 01, 2022 Filed Sep 6, 2022 20:09 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantShare Option · Derivative 65,420 $0.00 Strike: $11.97 $0.00
Disclosure

SEC source: 0001415889-22-009345 · form4-09062022_010905.xml · derivative · entry 4

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,420

Underlying: Class A Common Share · 65,420 shares

Expires 2032-08-31

F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022.

Read SEC document
July 15, 2022 Filed Sep 6, 2022 20:09 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantClass A Common Share 1,048 $9.56 $10,018.88
Disclosure

SEC source: 0001415889-22-009345 · form4-09062022_010905.xml · nonDerivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,261

F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2022 to July 15, 2022. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).

Read SEC document
April 07, 2022 Filed Apr 11, 2022 20:31 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantRestricted Share Unit · Derivative 10,905 $0.00 $0.00
Disclosure

SEC source: 0001415889-22-003992 · form4-04112022_010412.xml · derivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,905

Underlying: Class A Common Share · 10,905 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.

F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.

Read SEC document
April 07, 2022 Filed Apr 11, 2022 20:31 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantShare Option · Derivative 65,420 $0.00 Strike: $11.10 $0.00
Disclosure

SEC source: 0001415889-22-003992 · form4-04112022_010412.xml · derivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,420

Underlying: Class A Common Share · 65,420 shares

Expires 2032-04-06

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.

Read SEC document
March 21, 2022 Filed Mar 23, 2022 20:30 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionRestricted Share Unit · Derivative 4,611 $0.00 $0.00
Disclosure

SEC source: 0001415889-22-003282 · form4-03232022_040302.xml · derivative · entry 3

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Share · 4,611 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F2 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs.

F2 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs.

Read SEC document
March 21, 2022 Filed Mar 23, 2022 20:30 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Tax withholdingClass A Common Share 1,461 $10.98 $16,041.78
Disclosure

SEC source: 0001415889-22-003282 · form4-03232022_040302.xml · nonDerivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,213

Read SEC document
March 21, 2022 Filed Mar 23, 2022 20:30 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionClass A Common Share 4,611 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-22-003282 · form4-03232022_040302.xml · nonDerivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,674

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

Read SEC document
March 16, 2022 Filed Mar 18, 2022 20:36 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionRestricted Share Unit · Derivative 1,964 $0.00 $0.00
Disclosure

SEC source: 0001179110-22-002324 · edgar.xml · derivative · entry 5

Tessari Eben · CIK 0001867899 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,892

Underlying: Class A Common Share · 1,964 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.

F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.

Read SEC document
March 16, 2022 Filed Mar 18, 2022 20:36 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Tax withholdingClass A Common Share 681 $10.13 $6,898.53
Disclosure

SEC source: 0001179110-22-002324 · edgar.xml · nonDerivative · entry 4

Tessari Eben · CIK 0001867899 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,063

Read SEC document
March 16, 2022 Filed Mar 18, 2022 20:36 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 Exercise / conversionClass A Common Share 1,964 Not disclosed Not disclosed
Disclosure

SEC source: 0001179110-22-002324 · edgar.xml · nonDerivative · entry 3

Tessari Eben · CIK 0001867899 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,744

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

Read SEC document
January 15, 2022 Filed Mar 18, 2022 20:36 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantClass A Common Share 970 $9.63 $9,341.10
Disclosure

SEC source: 0001179110-22-002324 · edgar.xml · nonDerivative · entry 2

Tessari Eben · CIK 0001867899 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,780

F2 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2021 to January 15, 2022. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).

Read SEC document
September 02, 2021 Filed Sep 7, 2021 21:21 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantRestricted Share Units · Derivative 7,856 $0.00 $0.00
Disclosure

SEC source: 0001179110-21-008660 · edgar.xml · derivative · entry 2

Tessari Eben · CIK 0001867899 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,856

Underlying: Class A Common Shares · 7,856 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer.

F3 · derivative.exercise_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

F3 · derivative.expiration_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

Read SEC document
September 02, 2021 Filed Sep 7, 2021 21:21 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantShare Option · Derivative 47,138 $0.00 Strike: $12.97 $0.00
Disclosure

SEC source: 0001179110-21-008660 · edgar.xml · derivative · entry 1

Tessari Eben · CIK 0001867899 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,138

Underlying: Class A Common Shares · 47,138 shares

Expires 2031-09-01

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021.

Read SEC document
July 15, 2021 Filed Mar 18, 2022 20:36 UTC Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 GrantClass A Common Share 868 $11.49 $9,973.32
Disclosure

SEC source: 0001179110-22-002324 · edgar.xml · nonDerivative · entry 1

Tessari Eben · CIK 0001867899 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,810

F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 1, 2021 to July 15, 2021. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.